Clinical Research Directory

Inclusion Criteria: * Woman ≥ 18 years * Signed and written informed consent. * Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib - IVa, T1b or higher, any N, M0. * Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply; * T1b or larger tumour with (irresectable) groin metastases * T1b or larger tumour with a close relationship to and/or involvement of the urethra or anal sphincter * World Health Organization performance status of 0-2 * Adequate haematological function defined by platelet count \>100x10E9/L, absolute leukocyte \>3X10E9/L or neutrophil count (ANC) \>1.5x10E9/L, and hemoglobin \>6.0 mmol/L * Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal (ULN) range and ASAT and ALAT levels ≤2.5x ULN for all subjects * Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method) * Beta HCG level of 14 mIU/mL or below for women of childbearing potential * Highly effective contraception for patients if the risk of conception exists Exclusion Criteria: * Patients with highly suspicious or positive metastases to the pelvic lymph nodes \* Patients eligible for radical local excision without involvement of other organs * Any psychiatric condition that would prohibit the understanding or rendering of informed consent * Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol * Existing neuropathy which will hinder the intake of chemotherapy